Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Annu Rev Pharmacol Toxicol. 2011;51:243-66. doi: 10.1146/annurev-pharmtox-010510-100528.
Orexin-A and -B (also known as hypocretin-1 and -2) are neuropeptides produced in the lateral hypothalamus that promote many aspects of arousal through the OX1 and OX2 receptors. In fact, they are necessary for normal wakefulness, as loss of the orexin-producing neurons causes narcolepsy in humans and rodents. This has generated considerable interest in developing small-molecule orexin receptor antagonists as a novel therapy for the treatment of insomnia. Orexin antagonists, especially those that block OX2 or both OX1 and OX2 receptors, clearly promote sleep in animals, and clinical results are encouraging: Several compounds are in Phase III trials. As the orexin system mainly promotes arousal, these new compounds will likely improve insomnia without incurring many of the side effects encountered with current medications.
食欲素 A 和 -B(也称为下丘脑泌素 1 和 -2)是在下丘脑外侧产生的神经肽,通过 OX1 和 OX2 受体促进觉醒的许多方面。事实上,它们是正常觉醒所必需的,因为产生食欲素的神经元的丧失会导致人类和啮齿动物的嗜睡症。这激发了人们开发小分子食欲素受体拮抗剂作为治疗失眠症的新疗法的极大兴趣。食欲素拮抗剂,特别是那些阻断 OX2 或 OX1 和 OX2 受体的拮抗剂,在动物中显然能促进睡眠,临床结果令人鼓舞:几种化合物正在进行 III 期试验。由于食欲素系统主要促进觉醒,这些新化合物可能会改善失眠,而不会产生当前药物所遇到的许多副作用。